- Questions for the Committee

- 1a. Should the Food and Drug Administration (FDA) recommend that, if a plasma pool (or minipool) is found to be HAV NAT positive, the individual HAV NAT positive donor should be identified and notified of the test result?
- 1b. If so, should the FDA recommend that the implicated donor be deferred from donating for 3 months?
- 2. Should the FDA recommend that unpooled units from donors, that were donated within the 3 months prior to the HAV NAT positive collection, be quarantined?
- 3. Should the FDA recommend that recipients of transfused components from donors, that were donated within 3 months prior to the donation of the HAV NAT positive collection, be traced and notified?